Next Article in Journal
miR-20b and miR-451a Are Involved in Gastric Carcinogenesis through the PI3K/AKT/mTOR Signaling Pathway: Data from Gastric Cancer Patients, Cell Lines and Ins-Gas Mouse Model
Next Article in Special Issue
Human Melanoma-Cell Metabolic Profiling: Identification of Novel Biomarkers Indicating Metastasis
Previous Article in Journal
The Peroxisomal PTS1-Import Defect of PEX1- Deficient Cells Is Independent of Pexophagy in Saccharomyces cerevisiae
Previous Article in Special Issue
The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb
 
 
Review
Peer-Review Record

The miRNAs Role in Melanoma and in Its Resistance to Therapy

Int. J. Mol. Sci. 2020, 21(3), 878; https://doi.org/10.3390/ijms21030878
by Francesca Varrone 1,* and Emilia Caputo 2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2020, 21(3), 878; https://doi.org/10.3390/ijms21030878
Submission received: 13 December 2019 / Revised: 20 January 2020 / Accepted: 26 January 2020 / Published: 29 January 2020
(This article belongs to the Special Issue Molecular Biology of Melanoma)

Round 1

Reviewer 1 Report

The review:”  The miRNAs role in melanoma and in its resistance to therapy” is very extensive review.” Authors did a good job implementing available information about the miRNAs role in melanoma development.

The review:”  The miRNAs role in melanoma and in its resistance to therapy” is very extensive review.” Authors did a good job implementing available information about the miRNAs role in melanoma development. Melanoma is a deadly type of skin cancer and the proper therapy is not yet well defined. There are many different approaches to melanoma treatment, but none of them had high success rate in treatment of high-grade melanoma. Different drug approach to melanoma treatment has been employed, but high resistance rate to this therapy makes is more complex. In recent years melanoma-associated, miRNAs emerged as possible therapy, which authors have described in this review. Authors nicely described current melanoma treatment modalities in details and pros and cons of each method.

Author Response

Thank you for your comments. We appreciate that our goals in writing this review were reached.

Reviewer 2 Report

this manuscript describes the role of miRNA in melanoma and its therapeutic potential.

The review is well organized and comprehensive

Minor comments:

p3, l 76: the melanocytes are resistance to UV-induced apoptosis and not its damage (they actually accumulate more mutations due to the exposure)

Circadian rhythm has been reported as a key risk factor in melanoma Generation. the readers will benefit if this topic will be integrated (as a risk factor and gene regulation of miRNA)

  

Author Response

Response to Reviewer 2.

Comments and Suggestions for Authors

this manuscript describes the role of miRNA in melanoma and its therapeutic potential.

The review is well organized and comprehensive

Minor comments:

p3, l 76: the melanocytes are resistance to UV-induced apoptosis and not its damage (they actually accumulate more mutations due to the exposure)

Thank you for your notice. We clarify this point by modifying the text in: The melanocytes are resistant to UV-induced apoptosis. They continue to grow and to accumulate genetic mutations leading to the formation and growth of a melanoma [22] [23].

 

Circadian rhythm has been reported as a key risk factor in melanoma Generation. the readers will benefit if this topic will be integrated (as a risk factor and gene regulation of miRNA).

Thank you for your suggestion. We integrated this point in Melanoma Risk Factors Section p.3, lane 80 adding a sentence:  A role of circadian rhythm in melanoma development has been also reported. It has been demonstrated that melatonin, a major output product of circadian rhythm, play a protective role in melanoma, with the corresponding reference:  Markova-Car EP1, Jurišić D, Ilić N, Kraljević Pavelić S. Running for time: circadian rhythms and melanoma. Tumour Biol. 2014; 35(9):8359-8368.

The reader could benefit from the cited review, more detailed and specific for this topic, which was not one of ours in our manuscript.

Back to TopTop